MoonLake Immunotherapeutics (NASDAQ:MLTX) Sets New 12-Month Low – Should You Sell?

MoonLake Immunotherapeutics (NASDAQ:MLTX)’s share price hit a new 52-week low during trading on Monday . The stock traded as low as $36.64 and last traded at $36.75, with a volume of 310867 shares traded. The stock had previously closed at $38.04.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Needham & Company LLC raised their price objective on MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Thursday, February 27th. Finally, The Goldman Sachs Group decreased their target price on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a “buy” rating for the company in a research note on Thursday, February 27th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, MoonLake Immunotherapeutics presently has an average rating of “Buy” and a consensus price target of $83.20.

MoonLake Immunotherapeutics Stock Up 4.2 %

The stock has a market cap of $2.52 billion, a P/E ratio of -30.47 and a beta of 1.31. The firm’s 50-day moving average is $44.45 and its two-hundred day moving average is $48.46.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.09). Analysts anticipate that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Several institutional investors have recently bought and sold shares of MLTX. US Bancorp DE bought a new position in shares of MoonLake Immunotherapeutics in the 3rd quarter valued at approximately $44,000. Deutsche Bank AG grew its holdings in MoonLake Immunotherapeutics by 59.8% during the fourth quarter. Deutsche Bank AG now owns 903 shares of the company’s stock valued at $49,000 after purchasing an additional 338 shares during the last quarter. Birchview Capital LP bought a new position in shares of MoonLake Immunotherapeutics in the fourth quarter valued at approximately $217,000. KLP Kapitalforvaltning AS bought a new position in shares of MoonLake Immunotherapeutics in the fourth quarter valued at approximately $244,000. Finally, PEAK6 LLC acquired a new stake in shares of MoonLake Immunotherapeutics in the fourth quarter worth $271,000. 93.85% of the stock is currently owned by institutional investors.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.